[1] [1] IVANOV A A, BAKAREV M A, LUSHNIKOVA E L. Histological variants of papillary thyroid cancer in relation to clinical and morphological parameters and prognosis[J]. Bull Exp Biol Med, 2023, 174(5): 647-652.

[5] [5] HANEGE F M, TUYSUZ O, CELIK S, et al. Hashimoto's thyroiditis in papillary thyroid carcinoma: a 22-year study[J]. Acta Otorhinolaryngol Ital, 2021, 41(2): 142-145.

[6] [6] ZHANG Q, ALI M, WANG Y, et al. Galectin-1 binds GRP78 to promote the proliferation and metastasis of gastric cancer[J]. Int J Oncol, 2022, 61(5): 141.

[7] [7] MACH P, KIMMIG R, KASIMIR-BAUER S, et al. Association of soluble B7-H4 and circulating tumor cells in blood of advanced epithelial ovarian cancer patients[J]. Front Oncol, 2021, 11: 721067.

[9] [9] CROCKETT D J, FAUCETT E A, GNAGI S H. Thyroid nodule/differentiated thyroid carcinoma in the pediatric population[J]. Pediatr Ann, 2021, 50(7): e282-e285.

[11] [11] ZHU J, ZHENG Y, ZHANG H, et al. Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cellsviaactivation of the MAPK JNK/p38 signalling pathway[J]. Am J Transl Res, 2019, 11(6): 3862-3878.

[12] [12] GHEYSEN L, SOUMOY L, TRELCAT A, et al. New treatment strategy targeting galectin-1 against thyroid cancer[J]. Cells, 2021, 10(5): 1112.

[13] [13] MARTNEZ-BOSCH N, MANERO-RUPREZ N, MORENO M, et al. Exploring the role of galectins in cancer:in vitroandin vivoapproaches[J]. Methods Mol Biol, 2022, 2442: 685-711.

[14] [14] CORRAL J M, PUERTO-NEVADO L D, CEDEO M, et al. Galectin-1, a novel promising target for outcome prediction and treatment in SCLC[J]. Biomed Pharmacother, 2022, 156: 113987.

[16] [16] GENOVA C, TASSO R, ROSA A, et al. Prognostic role of soluble and extracellular vesicle-associated PD-L1, B7-H3 and B7-H4 in non-small cell lung cancer patients treated with immune checkpoint inhibitors[J]. Cells, 2023, 12(6): 832.

[17] [17] SONG X, ZHOU Z, LI H, et al. Pharmacologic suppression of B7-H4 glycosylation restores antitumor immunity in immunecold breast cancers[J]. Cancer Discov, 2020, 10(12): 1872-1893.

[18] [18] PODOJIL J R, MILLER S D. Potential targeting of B7-H4 for the treatment of cancer[J]. Immunol Rev, 2017, 276(1): 40-51.

[19] [19] YANG J, TIAN Z, GAO H, et al. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer[J]. BMC Cancer, 2022, 22(1): 584.

[21] [21] XU C H, WANG W, WANG Y C, et al. Diagnosis value of serum soluble B7-H4 expression in non-small cell lung cancer[J]. Clin Respir J, 2018, 12(1): 134-139.